Last Updated: May 12, 2026

Claims for Patent: 12,582,655

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,582,655

Title:	Methods of treating disorders using CSFIR inhibitors
Abstract:	Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Inventor(s):	Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US19/364,654
Patent Claims:	1. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound represented by: and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient about 2 mg to about 60 mg of the compound once a day, twice daily, every other day, once a week, twice weekly, or three times a week. 2. The method of claim 1, wherein the tenosynovial giant cell tumor is localized. 3. The method of claim 1, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 4. The method of claim 1, wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient about 5 mg to about 30 mg of the compound once a day, twice daily, every other day, once a week, twice weekly, or three times a week. 5. The method of claim 1, wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient about 30 mg of the compound twice weekly. 6. The method of claim 1, comprising administering to the patient the composition twice weekly for about 3 months. 7. The method of claim 1, comprising administering to the patient the composition twice weekly for about 6 months. 8. The method of claim 1, comprising administering to the patient the composition twice weekly for about 1 year. 9. The method of claim 1, comprising administering to the patient the composition twice weekly for about 2 years. 10. The method of claim 1, wherein the pharmaceutical composition is administered to the patient as a neo-adjuvant. 11. The method of claim 1, wherein the pharmaceutical composition is administered to the patient as an adjuvant. 12. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound represented by: and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient 30 mg of the compound twice weekly. 13. The method of claim 12, wherein the tenosynovial giant cell tumor is localized. 14. The method of claim 12, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 15. The method of claim 12, comprising administering to the patient the composition twice weekly for about 3 months. 16. The method of claim 12, comprising administering to the patient the composition twice weekly for about 6 months. 17. The method of claim 12, comprising administering to the patient the composition twice weekly for about 1 year. 18. The method of claim 12, comprising administering to the patient the composition twice weekly for about 2 years. 19. The method of claim 12, wherein the pharmaceutical composition is administered to the patient as a neo-adjuvant. 20. The method of claim 12, wherein the pharmaceutical composition is administered to the patient as an adjuvant. 21. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound represented by: and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide the patient a therapeutically effective amount of the compound. 22. The method of claim 21, wherein the tenosynovial giant cell tumor is localized. 23. The method of claim 21, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 24. The method of claim 21, comprising administering to the patient the composition twice weekly for about 3 months. 25. The method of claim 21, comprising administering to the patient the composition twice weekly for about 6 months. 26. The method of claim 21, comprising administering to the patient the composition twice weekly for about 1 year. 27. The method of claim 21, comprising administering to the patient the composition twice weekly for about 2 years. 28. The method of claim 21, wherein the pharmaceutical composition is administered to the patient as a neo-adjuvant. 29. The method of claim 21, wherein the pharmaceutical composition is administered to the patient as an adjuvant.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.